

AGENDA

**Uniform Formulary Beneficiary Advisory Panel (BAP)
27 March 2019 @ 9:00 AM**

**Naval Heritage Center Theater
701 Pennsylvania Ave., N.W., Washington, DC 20004**

- **Administrative Meeting (BAP members report no later than 7:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DHA Pharmacy Operations Division (POD) Formulary Management Branch (FMB) will present relative clinical and cost-effective analyses along with the DoD Pharmacy & Therapeutics Committee (P&T) recommendations for the Uniform Formulary (UF).

The P&T Committee made recommendations for the following drugs/drug classes during the February 2019 meeting:
- **Drug Class Reviews**
 - *Migraine Agents – Calcitonin Gene-Related Peptide (CGRP) Antagonists Subclass*
 - *Oncological Agents – 2nd-Generation Antiandrogens Subclass and CYP-17 Inhibitors Subclass*
- **Section 702, National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2018: TRICARE Tier 4/Not Covered Drugs per 32 CFR 199.21(e)(3)**
 - *Diabetes Non-Insulin – Biguanides Subclass: metformin ER (Glumetza)*
 - *Pain Agents – Combinations Subclass: naproxen/esomeprazole (Vimovo)*
 - *Pancreatic Enzyme Replacement Therapy (PERT): pancrelipase (Zenpep)*
 - *Targeted Immunomodulatory Biologics: brodalumab (Siliq)*
- **Newly Approved Drugs per 32 CFR 199.21(g)(5)**
 - *amifampridine (Firdapse) – Miscellaneous Neurological Agent for Lambert-Eaton Myasthenic Syndrome (LEMS)*
 - *aripiprazole tablet with ingestible event marker (Abilify MyCite) – Atypical Antipsychotic*

- *baloxavir (Xofluza) – Antiviral for Influenza*
- *cenegermin-bkbj ophthalmic solution (Oxervate) – Anti-Inflammatory Immunomodulatory Ophthalmic Agent for Neurotrophic Keratitis*
- *clobazam oral film (Sympazan) – Anticonvulsant-Antimania Agent for Lennox-Gastaut Syndrome*
- *cyclosporine 0.09% ophthalmic solution (Cequa) – Anti-Inflammatory Immunomodulatory Ophthalmic Agent for Dry Eye Disease*
- *desmopressin acetate sublingual (SL) tab (Nocdurna) – Miscellaneous Endocrine Agent for Nocturia due to Nocturnal Polyuria*
- *elapegademase-lvlr IM injection (Revcovi) – Miscellaneous Metabolic Agent for Adenosine Deaminase Severe Combined Immune Deficiency (ADA-SCID)*
- *filgrastim vials (Granix) – White Blood Cell Stimulant and Biosimilar to Neupogen*
- *gilteritinib (Xospata) – Oncological Agent for Acute Myelogenous Leukemia (AML)*
- *glasdegib (Daurismo) – Oncological Agent for AML*
- *halobetasol propionate 0.01% lotion (Bryhali) – High Potency Corticosteroid-Immune Modulator for Plaque Psoriasis*
- *halobetasol propionate 0.05% foam (Lexette) – corticosteroids-Immune Modulators – High Potency:*
- *inotersen injection (Tegsedi) – Miscellaneous Neurological Agent for Hereditary Transthyretin Amyloidosis*
- *itraconazole 65 mg capsules (Tolsura) – Antifungal Agent*
- *larotrectinib (Vitrakvi) – Oncological Agent for Solid Tumors*
- *latanoprost (Xelpros) – Ophthalmic Prostaglandin*
- *lorlatinib (Lorbrena) – Oncological Agent for Non-Small Cell Lung Cancer (NSCLC)*
- *loteprednol ophthalmic suspension (Inveltys) – Ophthalmic Corticosteroid for Postoperative Inflammation*
- *omadacycline (Nuzyra) – Tetracycline Antibiotic for Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSIs)*
- *pegfilgrastim-cbqv injection (Udenyca) – White Blood Cell Stimulant and Biosimilar to Neulasta*

- *revefenacin nebulized solution (Yupelri) – Pulmonary-2: Long-Acting Anti-Muscarinic Agent (LAMA) for Chronic Obstructive Pulmonary Disease (COPD)*
- *rifamycin (Aemcolo) – Miscellaneous Gastrointestinal Antibiotic for Traveler’s Diarrhea*
- *riluzole oral suspension (Tiglutik) – Miscellaneous Neurological Agent for Amyotrophic Lateral Sclerosis (ALS)*
- *sarecycline (Seysara) – Tetracycline Antibiotic for Acne Vulgaris*
- *tafenoquine 100 mg tablet (Arakoda) – Antimalarial Agent for Prophylaxis of Malaria*
- *tafenoquine 150 mg tablet (Krintafel) – Antimalarial Agent for Prevention of Relapse and Radical Cure of Malaria*
- *talazoparib (Talzenna) – Oncological Agent for Breast Cancer*
- *testosterone enanthate, SQ injection (Xyosted) – Androgens-Anabolic Steroids: Testosterone Replacement Therapies*

➤ **Utilization Management Issues**

➤ ***Prior Authorization Criteria—New Criteria***

- *Antihistamine-1: First Generation and Combinations – dexchlorpheniramine maleate 2 mg/5 mL oral solution (Ryclora)*
- *Hepatitis C Agents: Direct-Acting Agents: generic ledipasvir/sofosbuvir (Harvoni) and generic sofosbuvir/velpatasvir (Epclusa)*
- *Skeletal Muscle Relaxants and Combinations: Tricyclic Antidepressants: cyclobenzaprine 7.5 mg*

➤ ***Prior Authorization Criteria—Updated Criteria***

- *Cardiovascular Agents Miscellaneous: ivabradine (Corlanor)*
- *Cystic Fibrosis Agents: ivacaftor (Kalydeco)*
- *Gastrointestinal-2 Agents: Miscellaneous – rifaximin 200 mg (Xifaxan)*
- *Hematological Agents – Platelets: avatrombopag (Doptelet)*
- *Immune Modulators Endocrine Agents: Miscellaneous – desmopressin acetate nasal spray (Noctiva)*
- *Targeted Immunomodulatory Biologics (TIBs): adalimumab (Humira) and anakinra (Kineret)*

- **Brand over Generic Authorization for Dihydroergotamine Spray/Pump (Migranal Nasal Spray)**
- **Section 703, National Defense Authorization Act (NDAA) for Fiscal Year (FY) 2008**
- **Panel Discussions**

The Beneficiary Advisory Panel members will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendations and vote to accept or reject them. The Panel will provide comments on their vote as directed by the Panel Chairman.